{"id":539742,"date":"2021-04-21T18:58:01","date_gmt":"2021-04-21T18:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=539742"},"modified":"2021-04-21T18:58:01","modified_gmt":"2021-04-21T18:58:01","slug":"malignant-mesothelioma-market-industry-trends-drugs-companies-and-analysis-by-delveinsight-sellas-life-sciences-takeda-astrazeneca-targovax-aduro-biotech-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/malignant-mesothelioma-market-industry-trends-drugs-companies-and-analysis-by-delveinsight-sellas-life-sciences-takeda-astrazeneca-targovax-aduro-biotech-and-others_539742.html","title":{"rendered":"Malignant Mesothelioma Market: Industry trends, Drugs, Companies and Analysis by DelveInsight | SELLAS Life Sciences, Takeda, AstraZeneca, Targovax, Aduro Biotech and Others"},"content":{"rendered":"
\"Malignant<\/a><\/p>\n
\n
Malignant Mesothelioma Market<\/div>\n<\/div>\n<\/div>\n

Malignant Mesothelioma<\/strong>is a relatively rare but aggressive form of cancer most frequently a result of inhaling asbestos arising from the membrane covering the lungs and the inner side of the ribs. The symptoms of MM include breathlessness, cough, chest pain, fatigue, fevers, persistent cough, loss of appetite and unexplained weight loss, swollen figures and constipation. There is an extremely poor prognosis and a vast majority of MM patients who are diagnosed in an advanced stage.<\/p>\n

DelveInsight’s “Malignant Mesothelioma Market<\/a><\/strong> Insights, Epidemiology, and Market Forecast-2030<\/strong>” report delivers an in-depth understanding of the Malignant Mesothelioma, historical and forecasted epidemiology as well as the Malignant Mesothelioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

 <\/p>\n

Some of the key facts of the<\/strong> Malignant Mesothelioma Report:<\/strong><\/p>\n

    \n
  1. The annual incidence of Mesothelioma in the United States is estimated to be approximately 3,300 cases per year.<\/li>\n
  2. Around 70% of MM develops from documented asbestos exposure, usually after a 30–40 years latency period.<\/li>\n
  3. Malignant Mesothelioma (MM) is a rare tumor with an incidence<\/li>\n
  4. In Europe, the average incidence of MM is 20 per million inhabitants\/year<\/li>\n<\/ol>\n

     <\/p>\n

    Request for Free Sample Pages<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/malignant-mesothelioma-market<\/a><\/strong><\/p>\n

     <\/p>\n

    Key benefits of the<\/strong> Malignant Mesothelioma Report :<\/strong><\/p>\n

    1. Malignant Mesothelioma market report covers a descriptive overview and comprehensive insight of the Malignant Mesothelioma epidemiology and Malignant Mesothelioma  market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. Malignant Mesothelioma market report provides insights on the current and emerging therapies. <\/p>\n

    3. Malignant Mesothelioma market report offers a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

    4. Malignant Mesothelioma market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Malignant Mesothelioma market.<\/p>\n

     <\/p>\n

    Request for Free Sample Pages<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/malignant-mesothelioma-market<\/a><\/strong><\/p>\n

    “As per DelveInsight’s analysts, men are more often affected than women, and the incidence in males in the US is 1.5 per 100,000 per year.”<\/em><\/strong><\/p>\n

     <\/p>\n

    Some of Malignant Mesothelioma Companies are:<\/strong><\/p>\n